VeenaCharuMD

PubMed

• 8 citations
  Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
  Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak, Veena Charu, Roger M. Lyons, Jack Aiello, Kimberly Bogard, Renda H. Ferrari, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Nov 1
• 117 citations
  Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
  Ruben Niesvizky, Ian W. Flinn, Robert M. Rifkin, Nashat Y. Gabrail, Veena Charu, Billy Clowney, James Essell, Yousuf Gaffar, Thomas A. Warr, Rachel Neuwirth, Yanyan Zh...> ;Journal of Clinical Oncology. 2015 Jun 8
• 24 citations
  A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma.
  James R. Berenson, Ori Yellin, Hesaraghatta K. Shamasunder, Chien-Shing Chen, Veena Charu, Thomas B. S. Woliver, Shamel Sanani, Michael Schlutz, Youram Nassir, Regina ...> ;Supportive Care in Cancer. 2015 Jun 1
• Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
  Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saa...> ;Eur. J. Cancer. 2012-11-01
• Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma (MM) patients ineligible...
  Niesvizky R, Flinn IW, Rifkin RM, Gabrail N, Charu V, Gaffar Y, Neuwirth R, Corzo D, Reeves J> ;J. Clin. Oncol.. 2011-05-20
• A randomized, double-blind phase II trial of exemestane with or without MM-121 in postmenopausal women with locally advanced or metastatic estrogen receptor-positive (...
  Moyo VM, Higgins MJ, Aravelo-Araujo R, Iannotti N, Charu V, Dhindsa N, Goss PE> ;J. Clin. Oncol.. 2011-05-20
• 106 citations
  Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib
  Linda Mileshkin, Rodney J. Hicks, Brett G.M. Hughes, Paul Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea...> ;Clinical Cancer Research. 2011 Mar 1
• 11 citations
  TROPICS 1: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
  Nashat Y. Gabrail, Eric Sandler, Veena Charu, Nick Anas, Eduardo Lim, Martha Blaney, Mark Ashby, Barbara S. Gillespie, Susan M. Begelman> ;Journal of Vascular and Interventional Radiology. 2010 Dec 1
• 21 citations
  Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
  Enrique Hernandez, Peter Ganly, Veena Charu, Joseph Dibenedetto, Dianne Tomita, Tom Lillie, Kerry Taylor> ;Current Medical Research and Opinion. 2009 Aug 25
• Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV).
  Grous JJ, Riegel E, Gabrail N, Charu V, Arevalo-Araujo R, Yanagihara R, Nguyen A, Robertson P, Cooper B, O'Boyle E, Barr J> ;J. Clin. Oncol.. 2009-05-20
• 7 citations
  Initiation of epoetin-α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy
  John A. Glaspy, Veena Charu, Donghan Luo, Victor Moyo, Marc Kamin, Francois Wilhelm> ;Cancer. 2009 Mar 1
• 99 citations
  Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle Pegfilgrastim
  Lodovico Balducci, Hafez Al-Halawani, Veena Charu, Jennifer Tam, Seta Shahin, Lyndah Dreiling, William B. Ershler> ;The Oncologist. 2007 Dec 1
• 14 citations
  A Randomized, Open-Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy-Induced Anemia
  Veena Charu, Bruce Saidman, Ali Ben-Jacob, Glen R. Justice, Ajit S. Maniam, Dianne Tomita, Greg Rossi, Timothy Rearden, John A. Glaspy> ;The Oncologist. 2007 Oct 1
• 24 citations
  Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial
  Veena Charu, Chandra P. Belani, Ahmad N. Gill, Mukesh Bhatt, Dianne Tomita, Greg Rossi, Ali Ben-Jacob> ;The Oncologist. 2007 Jun 1
• 56 citations
  Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant
  Thomas Grote, Julio Hajdenberg, Alan Cartmell, Susan Ferguson, Angela Ginkel, Veena Charu> ;The Journal of Supportive Oncology. 2006 Sep 1
• Long-term tolerability of fentanyl effervescent buccal tablets: Interim analysis in patients with cancer-related breakthrough pain.
  Slatkin N, Charu V, Niebler G, Rauck R> ;J. Clin. Oncol.. 2006-06-20
• Finding an effective dose of fentanyl effervescent buccal tablets: Combined results of open-label titration.
  Wertheim MS, Jhangiani H, Niebler G, Charu V> ;J. Clin. Oncol.. 2006-06-20
• 18 citations
  Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
  David H. Henry, Lucio N Gordan, Veena Charu, Francois E. Wilhelm, Denise Williams, John Xie, Richard C Woodman> ;Current Medical Research and Opinion. 2006 Jun 13
• 24 citations
  Treatment of Chemotherapy-Induced Anemia in Breast Cancer: Results of a Randomized Controlled Trial of Darbepoetin Alfa 200 μg Every 2 Weeks Versus Epoetin Alfa 40,000...
  Frank M. Senecal, Lorrin Yee, Nashat Y. Gabrail, Veena Charu, Dianne Tomita, Greg Rossi, Lee S. Schwartzberg> ;Clinical Breast Cancer. 2005 Dec 1
• 65 citations
  Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 μg Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy
  Roger J. Waltzman, Christopher Croot, Glen R. Justice, Mark R. Fesen, Veena Charu, Denise Williams> ;The Oncologist. 2005 Sep 1
• Frequency of neutropenia-related events during chemotherapy and the use of pegfilgrastim and filgrastim in community practice: Results of the ACCEPT study.
  Campos LT, Folbe M, Meza L, Charu V, Dansey R, Xie F> ;J. Clin. Oncol.. 2005-06-01
• Pegfilgrastim and filgrastim patterns of use in community oncology practices: Results of the ACCEPT study.
  Meza LA, Charu V, Campos L, Davis D, Xie F> ;J. Clin. Oncol.. 2005-06-01
• 84 citations
  A Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia in Patients With Breast, Lung, or Gyn...
  Lee S. Schwartzberg, Lorrin Yee, Frank M. Senecal, Veena Charu, Dianne Tomita, Joel F. Wallace, Greg Rossi> ;The Oncologist. 2004 Nov 1
• Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy...
  Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Gallagher S, Charu V> ;J. Clin. Oncol.. 2004-07-15
• A controlled, randomized, open-label study to evaluate the effect of every-2-week darbepoetin alfa for anemia of cancer.
  Charu V, Belani CP, Gill AN, Bhatt M, Ben-Jacob A, Tomita D, Katz D> ;J. Clin. Oncol.. 2004-07-15
• Join now to see all